BROSSARD, QUEBEC – DIAGNOS inc. (“DIAGNOS” or the “Company”) (TSX VENTURE: ADK), a leader in early detection of serious health problems based on artificial intelligence, announces that the Board of Directors of the Company has approved (The “Plan”), so as to reduce the vesting period from three (3) years to two (2) years, Half (50%) of the options exercisable on the first anniversary of the grant date and the full number (100%) of options exercisable from the second anniversary of the grant date. This change is warranted to help DIAGNOS remain competitive in the future, Hiring and retention of the best candidates in artificial intelligence. All other provisions of the Plan remain unchanged.
This amendment is subject to the acceptance of the TSX Venture Exchange and the approval of the disinterested shareholders at the general meeting of shareholders of the Company scheduled for July 18, 2017.
Founded in 1998, DIAGNOS is a publicly funded Canadian public health organization whose mission is the early detection of health problems using its Computer Assisted Retina Analysis (CARA) artificial intelligence (AI) tool . CARA is an ophthalmic TV platform that integrates with current devices (hardware and software) and point-of-care processes. CARA’s artificial intelligence enhancement algorithms allow for sharper, clearer and easier to retrieve traditional retinal images. CARA is a secure Internet-based tool that is compatible with all brands of retouching, all recognized image formats and EMRs. CARA is a cost-effective tool for real-time screening in a large number of patients. CARA has been approved by regulatory agencies, including Canada (Health Canada), the United States (FDA), Europe and Mexico.
The TSX Venture Exchange and its regulatory services provider (as that term is defined in the policies of the TSX Venture Exchange) assumes no responsibility for the adequacy or accuracy of this release.
Source: DIAGNOS inc.